deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03165292

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Very High Risk Neuroblastoma
Interventions Autologous stem cell transplant Thiotepa Topotecan mIBG
Updated 18 times since 2017 Last updated: Aug 25, 2025 Started: Oct 1, 2018 Primary completion: Aug 28, 2023 Completion: Mar 28, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial

Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris

See all terminations from Gustave Roussy, Cancer Campus, Grand Paris

A PHASE2 clinical study on Very High Risk Neuroblastoma, this trial is terminated or withdrawn. The trial is conducted by Gustave Roussy, Cancer Campus, Grand Paris and has accumulated 18 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~Jun 2024 · 8 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded

  1. Oct 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 13 earlier versions

  1. Oct 2023 — Jun 2024 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Feb 2023 — Oct 2023 [monthly]

    Suspended PHASE2

  3. Jan 2023 — Feb 2023 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  4. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. Feb 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Nov 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE2

  11. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE2

  12. Aug 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

  13. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gustave Roussy, Cancer Campus, Grand Paris
  • National Cancer Institute, France
Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations